Evidence map›Paper›PMID 35326399›Full record

ArticleCells2022

Vav1 Promotes B-Cell Lymphoma Development.

Batel Shalom, Marganit Farago, Yaser Salaymeh, Shulamit Sebban, Eli Pikarsky, Shulamit Katzav

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Batel ShalomDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, P.O. Box 12272, Jerusalem 91120, Israel.
Marganit FaragoDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, P.O. Box 12272, Jerusalem 91120, Israel.
Yaser SalaymehDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, P.O. Box 12272, Jerusalem 91120, Israel.
Shulamit SebbanDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, P.O. Box 12272, Jerusalem 91120, Israel.
Eli PikarskyDepartment of Immunology and Cancer Research and Department of Pathology, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, Jerusalem 91120, Israel.ORCID 0000-0003-4186-7105
Shulamit KatzavDepartment of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Hadassah Medical School, Hebrew University, P.O. Box 12272, Jerusalem 91120, Israel.ORCID 0000-0002-6878-2139

Funding

Israel Cancer Association 20210002Israel Science Foundation 333/13
6 · The paper itself

Abstract

Vav1 is normally and exclusively expressed in the hematopoietic system where it functions as a specific GDP/GTP nucleotide exchange factor (GEF), firmly regulated by tyrosine phosphorylation. Mutations and overexpression of Vav1 in hematopoietic malignancies, and in human cancers of various histologic origins, are well documented. To reveal whether overexpression of Vav1 in different tissues suffices for promoting the development of malignant lesions, we expressed Vav1 in transgenic mice by using the ubiquitous ROSA26 promoter (Rosa Vav1). We detected Vav1 expression in epithelial tissues of various organs including pancreas, liver, and lung. While carcinomas did not develop in these organs, surprisingly, we noticed the development of B-cell lymphomas. Rac1-GTP levels did not change in tissues from Rosa Vav1 mice expressing the transgenic Vav1, while ERK phosphorylation increased in the lymphomas, suggesting that signaling pathways are evoked. One of the growth factors analyzed by us as a suspect candidate to mediate paracrine stimulation in the lymphocytes was CSF-1, which was highly expressed in the epithelial compartment of Rosa Vav1 mice. The expression of its specific receptor, CSF-1R, was found to be highly expressed in the B-cell lymphomas. Taken together, our results suggest a potential cross-talk between epithelial cells expressing Vav1, that secrete CSF-1, and the lymphocytes that express CSF-1R, thus leading to the generation of B-cell lymphomas. Our findings provide a novel mechanism by which Vav1 contributes to tumor propagation.

Indexed as

LymphomaLymphoma, B-CellAnimalsGuanosine TriphosphateHumansMacrophage Colony-Stimulating FactorMiceProto-Oncogene Proteins c-vavReceptor Protein-Tyrosine KinasesGuanosine TriphosphateMacrophage Colony-Stimulating FactorProto-Oncogene Proteins c-vavReceptor Protein-Tyrosine KinasesVAV1 protein, humanB-cell lymphomaRac-GTPRosa26Vav1

Identifiers

PMID35326399
PMCPMC8946024
OpenAlexW4221013739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.